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Purpose: The etiopathogenesis of drug-induced liver injury (DILI) is still far from being
elucidated. This study aims to the study of genetic variations in DILI, related to the drug
target, and specifically in the genes coding for the cyclooxygenase enzymes.
Methods: By using Next-generation Sequencing we analyzed the genes coding for
COX enzymes (PTGS1 and PTGS2) in 113 individuals, 13 of which were patients with
DILI caused by COX-inhibitors.
Results: The key findings of the study are the increased frequency, among DILI patients,
of SNPs causing alterations in transcription factor binding sites and non-synonymous
PTGS gene variants, as compared to control subjects. Moreover, the association with
non-synonymous SNPs was exclusive of DILI patients with late-onset (50 days or more)
Pc < 0.001 as compared to DILI patients with early onset, or with control subjects.
Conclusions: Our findings suggest an interaction of long-term exposure to COX
inhibitors combined with functional variants of the COX enzymes in the risk of developing
DILI. This is a novel observation that might have been overlooked by previous genetic
studies on DILI because of the limited coverage of PTGS genes in exome chips.
Keywords: PTGS1, PTGS2, next generation sequencing, drug-induced liver injury, COX1, COX2
BACKGROUND
Although drug-induced liver injury (DILI) is a rare adverse drug event, it is often life-threatening
because of the risk of developing acute liver failure. The mechanisms underlying DILI risk are
not well understood and hence, the search for biomarkers of DILI risk is a major research field
that aims to identify markers that could be used as both proof of the mechanisms involved and
of the risk factors that can be used for DILI prediction, as has already been done with many
pharmacogenomics biomarkers (Lucena et al., 2008, 2010; Agúndez, 2009; Agundez et al., 2009,
2011; Andrade et al., 2009; Robles-Diaz et al., 2016; Nicoletti et al., 2017). There are presently several
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independent hypotheses to explain idiosyncratic DILI, but none
of these is able to explain all the circumstances in which
DILI occurs.
Some genetic biomarkers for DILI either mechanistically-
based using a case-control strategy or with a GWAs/exome
sequencing approaches have been identified [for a review,
see (Robles-Diaz et al., 2016)]. However, the involvement of
genetic changes in DILI risk (for instance HLA risk alleles)
has been documented for only a few drugs (Kaliyaperumal
et al., 2018). On the other hand, case-control genotyping
studies, GWAS and exome sequencing have important
limitations because only some SNPs are tested, and most
of the target sequence is not checked. To overcome
this problem, deep sequencing comprising whole genes
is necessary.
In this study, we analyzed the potential effect of mutations in
cyclooxygenase genes (PTGS1 and PTGS2) on DILI risk related
to NSAIDs. From a mechanistic point of view, such a risk could
be related to genetic alteration in the arachidonic acid pathways,
which are closely related to inflammation. On the other hand,
adverse drug events for drugs acting on the COX enzymes
(that is, COX inhibitors) may be more likely if COX activity
is altered because of genetic variations. For this reason, we
analyzed patients who developed DILI after the administration
of COX-inhibitors and healthy individuals who tolerated
COX-inhibitors.
CASE PRESENTATION
Thirteen patients (8 women and 5 men) who experienced
DILI caused by COX inhibitors and 100 individuals who
tolerated COX-inhibitors at standard doses were included in
this study. The culprit drug for DILI and clinical details
of patients are shown in Table 1. Gender-matched control
individuals who tolerated COX-inhibitors (62 women and 38
men) individuals were recruited among staff and medical
students of the Hospitals and the Universities participating
in this study. Individuals which were considered as healthy
after medical examination, to exclude pre-existing disorders
and history of adverse events after the use of COX-inhibitors,
were asked to participate and over 95% of these agreed
to do so. We selected consecutive control subjects matched
with patients for drug exposure: Fifty control subjects who
have received ibuprofen within the previous month to sample
collection, 20 who received diclofenac, 10 indomethacin, 10
naproxen, and 10 rofecoxib. These frequencies match with the
frequencies for the DILI patients, except that no control subject
received nimesulide since this drug was discontinued from the
Spanish market due to liver safety. Both patients and controls
were Caucasian Spanish individuals. Written informed consent
for participation in this case report was obtained from all
Abbreviations: COX, Cyclooxygenase, prostaglandin-endoperoxide synthase;
NSAID, Non-steroidal anti-inflammatory drug; DILI, Drug-induced liver injury;
GWAS, Genome-wide association study; SNP, Single nucleotide polymorphism;
HLA, Human leukocyte antigen; PTGS1, Prostaglandin-Endoperoxide Synthase 1;
PTGS2, Prostaglandin-Endoperoxide Synthase 2.
participants. The protocol for this study was in accordance
with the Declaration of Helsinki and its subsequent revisions
and was approved by the respective Ethics Committees of the
participating Hospitals.
DESCRIPTION OF LABORATORY
INVESTIGATIONS AND DIAGNOSTIC
TESTS
To achieve complete gene capture, we sequenced all exons,
intron-exon boundaries as well as the 5′ and 3′ flanking
regions for both genes. Referred to the GRCh37 assembly
of the human genome, the sequences studied were the
following: PTGS1: Chromosome 9:125.131.159 to 125.158.017;
PTGS2: Chromosome 1:186.640.825 to 186.651.605. Partially
overlapping amplicons with a size lower than 400 bp were
designed. A total of 62 CS1/CS2 tagged primer pairs were
synthesized and used to amplify 113 DNA samples using
the Access Array platform (Fluidigm). During amplification,
samples were labeled with standard MID barcodes designed
for the FLX454 sequencing system. After amplification and
MID-labeling, individual amplicon libraries were analyzed using
a Bioanalyzer 2100 (Agilent) and bioanalyzer traces were
used to estimate the amplicon concentration for each sample.
Samples were then pooled, and libraries were purified by SPRI
using Ampure beads to remove all possible traces of small
molecules, primers, primer-dimers, or any other contaminants.
The pooled library was again quantified and titrated so that
a final amount of 1.95E+10 molecules with an enrichment
percentage of 7% was loaded on a Pico Titer Plate (Roche)
for a 200-cycle titanium-based sequencing run, made on FLX-
454 equipment. Reads were processed using an amplicon
processing pipeline and sff files were used for further analyses.
Coverage averaged around 50x for the whole project. Coverage
for the SNPs identified (shown in Supplemental Table 1) was
always over 50x. Sequencing reads were de-multiplexed and
aligned using the Amplicon Variant Analyzer software v2.8
(Roche) so that reads for each particular sample- target region
combination were analyzed in search of variants. Details
of the amplification and sequencing primers are available
in Supplemental Table 1.
The putative effect on the non-synonymous variants identified
in silico was assessed by using the Sorting Tolerant form
Intolerant (SIFT) and Polymorphism Phenotyping (PolyPhen)
scores as shown in the 1,000 genomes website for every SNP,
as well as the online application MutationAssessor (http://
mutationassessor.org/r3/).
RESULTS
The sequencing results (summarized in Table 2) reveal that
PTGS genes are well conserved. Although dozens of PTGS1
and PTGS2 single nucleotide polymorphisms (SNPs) have been
described to occur in Caucasian populations (see Agúndez
et al., 2015), our findings show that most of these SNPs
were not identified, or were extremely rare, in this cohort.
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TABLE 3 | Detailed genotype distribution for relevant SNPs.
Coordinate GRCh37.p13
(GCA_000001405.14)
rs ID Effect Patients with late-onset DILI
N = 5
(Non carriers / heterozygous/
homozygous); MAF
Rest of DILI patients
N = 8
(Non carriers / heterozygous/
homozygous); MAF
Control individuals
N = 100
(Non carriers / heterozygous/
homozygous); MAF
9:125131832 rs10306225 UGV 3/0/2; 0.400 8/0/0; 0.000 100/0/0; 0.000
9:125133479 rs1236913 MSV 2/3/0; 0.300 8/0/0; 0.000 88/11/1; 0.065
9:125133507 rs3842787 MSV 3/2/0; 0.200 8/0/0; 0.000 89/10/1; 0.060
9:125140823 rs5787 MSV 4/0/1; 0.200 8/0/0; 0.000 100/0/0; 0.000
9:125143707 rs3842792 MSV 4/1/0; 0.100 8/0/0; 0.000 100/0/0; 0.000
1:186646005 rs3218622 MSV 4/1/0; 0.100 8/0/0; 0.000 100/0/0; 0.000
MAF, Minor allele frequency; UGV, Upstream gene variant; MSV, Missense variant.
TABLE 4 | Haplotype analysis.
Haplotype frequencies rs10306225 rs1236913 rs3842787 rs5787 rs3842792 rs3218622 Frequency
(Total)
Frequency
(late-onset DILI
cases)
Frequency (controls)
1 A T C G A C 0.9048 0.300 0.935
2 A C T G A C 0.0619 0.100 0.060
3 T T C A A C 0.0095 0.200 NA
4 A C C G A C 0.0048 NA 0.005
5 A T C G A T 0.0048 0.100 NA
6 T C C G A C 0.0048 0.100 NA
7 T T C G A C 0.0048 0.100 NA
8 T T C G A C 0.0048 0.100 NA
9 T T C G A C 0.0048 0.100 NA
Haplotype association
with late-onset DILI
rs10306225 rs1236913 rs3842787 rs5787 rs3842792 rs3218622 Frequency
(Total)
OR (95% CI) P-value
1 A T C G A C 0.9048 1.00 —
2 A C T G A C 0.0619 0.09 (0.01–1.43) 0.0910
Rare haplotypes * * * * * * 0.0333 0.00 (0.00–0.09) 0.0024
Global haplotype association p < 0.0001.
NA, not applicable; *any nucleotide.
Interestingly, most of the PTGS1 and PTGS2 SNPs included
in the Illumina human exome chip or human core exome
chip (Urban et al., 2012) are also absent in this study
group. This raises doubts about the coverage of exome
chips to identify genetic associations related to PTGS1 and
PTGS2 genes.
In the whole population study, we identified 31 single
nucleotide polymorphisms (SNPs) for PTGS1, including four
non-synonymous SNPs. For PTGS2 we identified 31 SNPs
including one non-synonymous. We observed an increased
frequency of PTGS1 and PTGS2mutations among DILI patients,
as compared to that observed in control individuals. Most
of the SNPs identified in patients were rare among control
individuals and were rare also according to the 1,000 genomes
database (as shown in Table 2). All patients but one (case 1
in Table 2) had mutations at the PTGS1 gene and all patients
but one (case 5 in Table 2) had mutations at the PTGS2 gene.
Table 3 summarizes the comparison of relevant SNPs across
patients with late-onset DILI, the rest of DILI patients and
control individuals.
DISCUSSION OF THE UNDERLYING
PATHOPHYSIOLOGY AND THE NOVELTY
OR SIGNIFICANCE OF THE CASE
The most remarkable findings in this study are the presence
among DILI patients of SNPs causing alterations in transcription
factor binding sites such as the PTGS1 SNP rs10306225 (Agundez
et al., 2014), and the PTGS2 SNPs rs4648253, rs689466, and
rs20417, as well as non-synonymous SNPs such as PTGS1
rs1236913 (W 8 R), rs3842787 (P 17 L), rs5787 (R 108
Q), rs3842792 (K 185 T), and PTGS2 rs3218622 (R 228H).
These missense variants are extremely rare among European
individuals (Agúndez et al., 2015). The putative effects of
the most relevant SNPs shown in Table 3 have been revised
elsewhere (Agúndez et al., 2015). In brief, besides the rs10306225
SNP, which is a promoter variant that causes a modification
in a CDX1 binding site (Agundez et al., 2014), the rest of
SNPs are non-synonymous. According to functional predictions
and functional analyses (reviewed in Agúndez et al., 2015)
the SNPs rs1236913, rs3842787 have a little functional effect,
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although clinical associations for these SNPs with urticaria
induced by NSAIDs (Cornejo-Garcia et al., 2012) andmyocardial
infarction/stroke (Lee et al., 2008; Lemaitre et al., 2009; Gao et al.,
2014), respectively, have been proposed. The functional effect
of the rs5787 SNP is unknown, although functional prediction
suggests a mild functional impact (see Table 2), rs3842792 SNP
is predicted as functional (Table 2), but in vitro findings suggest
reduced functionality (Lee et al., 2007), and no functional impact
for the PTGS2 SNP rs3218622 has been described.
No particular association of missense SNPs with culprit drug,
age, gender, clinical presentation, type of liver injury, and severity
of the disease was identified. However, as shown in Table 1,
there is heterogeneity in the duration of treatment before DILI
onset. This heterogeneity, rather than being a weakness, is a
strong point in this study because it allowed discriminating
the frequencies of PTGS gene variations in DILI patients with
late and short-term onset. All the five DILI patients with the
longest times to DILI onset (50 or more days; patients n◦ 3,
8, 9, 10, 12 in Table 1) had missense variants, and no patient
with shorter time to DILI onset had such missense variants.
The intergroup comparison values for carriers of any non-
synonymous PTGS variants were as follows: Patients with late
DILI onset (50 or more days) vs. the rest of DILI patients (P
< 0.001). Patients with late DILI onset vs. control individuals
(P < 0.001). By turn, no significant differences for carriers of
non-synonymous PTGS variants were observed among patients
with DILI onset shorter than 50 days and control subjects (P =
0.325). Haplotype analyses (Table 4), and linkage disequilibrium
(LD) analyses (Supplemental Table 2), show that the risk is due
to the presence of rare haplotypes (containing missense variants)
in the group of patients with late-onset DILI, but it is not due to
LD variations for these variants. The strong association observed
in this report, although it is based in five cases only, suggests a
relationship of non-synonymous PTGS gene variations with DILI
onset after long-term NSAID therapy. This is a novel observation
that has not been raised by previous studies. Although the
putative role of PTGS gene variations has been explored using
the Illumina human exome chip or human core exome chip,
it is of note that chip coverage was very limited for PTGS
genes (Urban et al., 2012). By turn, this study has complete
coverage thus allowing the identification of, as yet, disregarded
SNPs. Another relevant difference with most DILI genetic
studies is that in this report we stratified patients according
to the time to onset. It cannot be ruled out heterogeneity in
the etiopathogenesis of DILI, and it is conceivable that the
mechanisms involved in DILI with a late onset might be different
from those involved in immediate or short-latency reactions.
This study, albeit with the inherent limitations of statistical
power that case reports have, reinforces the view that a complete
gene coverage and a detailed phenotype stratification of DILI
patients could be essential to gain strength in further genetic
association studies.
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